Use of topical bevacizumab for conjunctival intraepithelial neoplasia.

Abstract

PURPOSE:

To report our experience in the treatment of intraepithelial neoplasia of the conjunctiva using topical bevacizumab.

METHODS:

Ten eyes of 10 patients with conjunctival neoplasia received 25 mg/mL bevacizumab topically. Changes in the lesions were documented weekly using digital photography. After topical treatment, excisional biopsy was performed.

RESULTS:

The mean age of the patients was 60.5 ± 12 (33-77) years. The mean duration of topical treatment was 7.8 ± 1.3 (5-14) weeks. The size and vascularity of the tumors reduced weekly. All patients underwent excisional biopsy, cryotherapy, and amnion membrane transplantation. The histopathologic diagnosis of the lesions was carcinoma in situ. No recurrence was observed during the follow-up of patients for 6 months.

CONCLUSIONS:

Topical bevacizumab is an effective treatment to reduce the tumor size before surgery and may be a good alternative for adjuvant therapy of conjunctival neoplasms.

• Authors: Altan A Özcan, Emine Çiloğlu, Ebru Esen, Göksu H Şimdivar
• Journal: Cornea (Cornea) Vol. 33 Issue 11 Pg. 1205-9 (Nov 2014) ISSN: 1536-4798 [Electronic] United States
• PMID: 25014150 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Ophthalmic Solutions
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Administration, Topical
• Adult
• Aged
• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Biopsy
• Carcinoma in Situ (blood supply, drug therapy, pathology)
• Conjunctival Neoplasms (blood supply, drug therapy, pathology)
• Cryotherapy
• Female
• Humans
• Male
• Middle Aged
• Neovascularization, Pathologic (drug therapy, pathology)
• Ophthalmic Solutions
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)